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Abstract 
This clinical review will summarize the avail-  able data regarding the effect of either physiological or 
increased glucocorticoid concentrations on glucose metab- olism and insulin-sensitivity, in order to clarify the 
role, if any, of subclinical Cushing’s syndrome (SCS), a status of altered hypothalamic–pituitary–adrenal axis 
secretion in the absence of the classical signs or symptoms of overt cortisol excess, in patients with adrenal 
incidentalomas (AI) and diabetes mellitus type 2. Focusing on patients with SCS associated to AI, while there 
is convincing evidence in the literature that even a mild hyper cortisolemia is associated with alterations of 
glucose metabolism, evidence is insuffi- cient to conclude that the simple correction of chronic, even mild, 
hypercortisolism can completely revert metabolic, mainly glycemic alterations. At the same time, considering 
the variability of the prevalence of Cushing’s syndrome in patients with diabetes mellitus type 2 reported in 
the litera ture, no agreement does exist whether screening for CS can be useful and recommended in those 
patients. 
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Introduction 
Subclinical Cushing’s syndrome (SCS) is defined as a status of altered hypothalamic–pituitary–adrenal (HPA) 
axis secretion in the absence of the classical signs or symptoms of overt cortisol excess [1–4]. The interest in 
SCS is due to its high prevalence in some patient’s cate- gories, as those with adrenal incidentalomas (AI). 
Although SCS by definition is not associated with signs and/or symptoms specific to overt cortisol excess, 
such as purple striae, easy bruising, proximal muscle weakness, and plethora [5], some evidence suggests that 
this condition may lead to long-term consequences of cortisol excess that are similar to those present in overt 
Cushing’s syndrome (CS), like gluco-metabolic alterations  [4]. 
This clinical review will summarize the available data regarding the effect of either physiological or increased 
glucocorticoid concentrations on glucose metabolism and insulin-sensitivity, in order to clarify the role, if any, 
of subclinical hypercortisolism in patients with AI and dia- betes mellitus type  2. 
 
Glucocorticoids and  glucose metabolism 
Glucocorticoid hormones (GCs) are produced in the adre- nal cortex under the control of the HPA axis and act 
at different target tissues by binding two different intracel- lular receptors, the glucocorticoid receptor (GR) 
and the mineralcorticoid receptor (MR) [6]. On the other hand, it is well known that the effects of GCs vary 
considerably between subjects, due to a different sensitivity, which is at least partially, genetically determined 
[7, 8]. Moreover, other factors that modulate the biological effects of GCs in target tissues has been 
recognized: among them, the    11b-hydroxysteroid dehydrogenase (11b-HSD) enzymes, which interconvert 
cortisol and its inactive metabolite cortisone, are of particular interest: 11b-HSD type 1, which is pre- 
dominantly expressed in liver and adipose tissue, amplifies local GC action by conversion of cortisone to 
cortisol, whereas 11b-HSD type 2, which is mainly expressed in the kidney, reduces GC-induced effects by 
converting cortisol to cortisone [9]. 
In humans, blood glucose levels are determined mainly through the balance between insulin-dependent 
glucose production and muscle glucose utilization. GCs are so named based on their actions on carbohydrate 
metabolism, namely on insulin-dependent processes [10–13]. In partic- ular, the effect of GC includes 
increased hepatic glucose production, decreased insulin-dependent glucose uptake into peripheral tissues, 
breakdown of muscle and fat to provide additional substrates for glucose production, and inhibition of insulin 
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release from pancreatic b cells [10, 11]. The mechanisms by which GCs achieve these effects are 
multifactorial, as demonstrated by in vitro and in vivo studies [10–13]. 
At hepatic level, GCs increase endogenous glucose production both directly and indirectly, the latter by 
antagonizing insulin’s metabolic actions, through a number of proposed mechanism. Specifically, GCs 
increase glu- coneogenesis stimulating specific rate-limiting enzymes (e.g., phosphoenolpyruvate 
carboxykinase, and glucose-6- phospahatase), favoring the availability of free fatty acids and aminoacids, 
facilitating metabolite transport across the mitochondrial membranes, and finally potentiating the effects of 
other glucoregulatory hormones, such as gluca- gons and epinephrine [10, 11]. Finally, a role for the nuclear 
peroxisome proliferator-activated receptor-alfa (PPAR)-a in facilitating the GC-induced gluconeogenesis has 
recently been reported [14], and very recent studies have shown that the nuclear liver receptor LXRb plays a 
pivotal role in the development of GC-related hypergly- cemia, at least in mice  [15]. 
At peripheral levels, namely in skeletal muscle tissue that accounts for 80% of insulin-induced glucose 
disposal, GCs reduce the insulin-mediated glucose uptake either by directly interfering with several 
components of the insulin signaling cascade or modulating protein and lipid metab- olism. In particular, in 
animal models, GCs have been reported of being able to reduce the expression and phos- phorylation of 
insulin receptor substrate (IRS)-1, phos- phatidylinositol 3-kinase (PI3-K), and protein kinase B (PKB)/Atk, 
and to reduce the migration of glucose trans- porter GLUT-4 to cell surface [10, 11]. To date, few data do exist 
regarding the effects of GC on insulin signaling in humans, while a reduction in glycogen synthesis rates has 
been reported [11]. Moreover, GCs inhibit protein syn- thesis by reducing transport of aminoacids into the 
muscle, stimulate muscle proteolysis by activating a number of proteolytic systems (e.g., muscle ring finger-1 
and Atrogin- 1 protein), and induce adipose lipolysis, resulting in an increase of aminoacids, nonesterified 
fatty acids and tri- glycerides, which, in turn, interfere with IRS-1- and PI3-K- mediated insulin signaling, as 
demonstrated in animal models [11]. 
In addition to their effects on insulin sensitivity, GCs also inhibit insulin secretion from pancreatic b-cells, as 
demonstrated in animal models, by reducing the glucose uptake through the suppression of GLUT-2 
expression and glucokinase,  the  glucose  oxidation  by  enhancing inward 
repolarizing  K?  currents,  which  limit  calcium influx, 
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decreasing protein kinase’s A and C activation [11]; finally, GCs decrease insulin biosynthesis by reducing 
ATP/ADP ratio, inducing b cells apoptosis directly and indirectly, through lipotoxicity due to elevated plasma 
concentration of free fatty acids [11, 16]. In humans, GCs exert an acute inhibitory effects on insulin secretion 
in vitro and in vivo, while strong evidence about an inhibitory effects on b cell after chronic hypercortisolism 
is currently lacking [11, 17]. Central actions of GCs may enhance vagal stimulation of insulin secretion [18]. 
The balance of all the above mentioned effects of GCs is important in determining whether insulin resistance 
is accompanied by compensatory hyperinsulinemia or hyperglycemia, and may explain in part why only some 
patients with hypercortisolism develop glucose intolerance [19, 20]. 
 
Subclinical Cushing’s syndrome in patients with AI: focus on glucose metabolism  derangement 
The majority of the studies regarding the diagnosis and the treatment of SCS have been focused on series of 
patients with AI, clinically unapparent adrenal masses serendipi- tously found by abdominal imaging 
procedures for unre- lated diseases, that are thought to be present in up to 1–9% of adults, with a higher 
prevalence in elderly subjects [21– 29]. SCS is estimated to be present in 5–30% of patients with AI [1–4, 30–
34]. 
The variability in the prevalence of SCS in this group of patients depends on differences in the inclusion 
criteria, study design, work-up protocols, and mainly diagnostic criteria of SCS [1–4,  34]. 
The diagnosis of SCS is a challenge for clinicians due to several causes. First, it includes a heterogeneous 
spectrum of clinical phenotype that mainly depends on the variability of cortisol secretion that is distributed 
continuously from apparently non-functioning adrenal adenomas to overtly cortisol-producing adenomas, as 
well as on peripheral cortisol    sensitivity    [1–4].    As    a    consequence,    the identification of subtle signs 
of cortisol excess depends mainly on the personal practice of the physician, and may, therefore, be overlooked 
by those with less expertise with hypercortisolemic patients [4]. Second, no gold standard diagnostic tests to 
identify abnormal cortisol levels exist. In fact, although the 1-mg dexamethasone test (DST) is considered the 
most valuable test to screen for SCS, diagnosing SCS by arbitrary cortisol cutoffs at DST leads to unavoidable 
mistakes in classifying some patients, being cortisol secretion a continuum from completely normal to clearly 
increased levels and highly variable in the same individual [4]. Moreover, the reliabilities of other sug- gested 
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markers of HPA axis activity for the diagnosis of SCS, including high midnight serum cortisol level, low 
serum ACTH levels, high 24-h urinary free cortisol and  low serum DHEAS levels, are low in SCS   [4]. 
Despite diagnostic difficulties, several studies have demonstrated that a chronic, albeit slight, cortisol excess is 
able to induce the classic metabolic and cardiovascular complications of overt CS, such as arterial 
hypertension, obesity, or diabetes mellitus [5, 19, 20], together with bone disorders, like osteoporosis and 
fragility fractures [5, 35]. Unfortunately, all these comorbidities are very frequent in the elderly population, 
and they cannot be considered as specific features of SCS, which are, as above mentioned, more frequent in 
the elderly. However, there is still scarce information regarding the long-term detrimental effects, if any, of 
SCS [4]. 
Focusing on glucose metabolism, while an increased prevalence of impaired glucose tolerance or diabetes has 
been described at the diagnosis in patients with SCS, compared with non-functioning adenomas or controls 
[30, 32–34, 36, 37], these data were not confirmed by other studies that have reported a similar prevalence of 
impaired glucose metabolism in SCS than in the overall series of AI as well as in the general population [31, 
38–43]; some of these studies suggest a particular role of aging in the development of unfavorable metabolic 
outcome [43] (Table 1). The variability in the prevalence of glucose metabolism impairment in SCS may 
depend on variability of method used; in fact, in some studies, fasting glucose and fasting insulin have been 
evaluated [30, 36, 39], while in others, the diagnosis has been performed by an oral glucose tolerance test [33, 
34, 37, 40, 42, 43] that has been considered the gold standard test in CS [19, 20]. In fact, more than one half of 
patients with endogenous CS and diabetes were shown to have normal fasting glucose [19, 20]. Glycated 
hemoglobin, very recently added among the tools used for the diagnosis of diabetes mellitus, may be even 
more helpful in the clinical setting of SCS because this parameter is an integrated measure of glucose 
homeostasis, although its use in patients with SCS is not yet a standard practice [19,  20]. 
 The results of these studies suggest that chronic mild hypercortisolism, such as in SCS, may be associated 
with the clinical phenotype of the insulin resistance syndrome or that, as an alternative hypothesis, AI may 
itself be an unrecognized manifestation of the metabolic syndrome. In fact, it has been shown that insulin is 
mitogenic, being able to stimulate adrenal cortex cell proliferation and tumor formation in a time and in a 
dose-dependent matter,  without affecting cortisol synthesis [44]. In a recent study, Muscogiuri et al. [45] 
demonstrated a direct correlation between insulin resistance, evaluated by hyperinsulinemic euglycemic 
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clamp, and the size of the mass, in  patients with clinically non-functioning AI, suggesting that clini- cally 
undetectable hypercortisolism may cause insulin resistance and compensatory hyperinsulinemia, responsible 
itself for tumor growth. 
Normalization of hypercortisolism is the first step for the achievement of metabolic control in patients with 
overt or subclinical CS. Contrary to adrenal overt CS, where adre- nalectomy is the therapeutic gold standard, 
surgical approach might be proposed to patients with SCS, although long-term prospective studies assessing 
the metabolic outcome of patients with SCS and their follow-up are limited, with results sometimes discordant. 
In particular, whether patients with SCS should benefit from adrenalec- tomy is still a matter of debate, with 
the effect of adre- nalectomy on glucose metabolism impairment being controversial [31, 46–52]. 
A number of underpowered studies have reported an improvement in hyperglycemia and insulin sensitivity in 
patients with SCS after adrenalectomy, compared to those without SCS [31, 46–52]. In a case–control study, 
Erbil     et al. [48] compared the outcome of adrenalectomy between 28 patients with overt CS and 11 patients 
with SCS: they found that diabetes mellitus improved more frequently among patients with the subclinical 
syndrome. Tsuiki et al. [50] followed up 20 patients with SCS for 15–69 months: 10 of them were submitted to 
adrenalec- tomy, and the remaining patients were managed conser- vatively. Of the total patients, eight 
patients benefited from surgery in terms of better control of hyperglycemia, whereas half of the non-operated 
patients showed wors- ening of their clinical conditions, while the others remained unchanged. Toniato et al. 
[51] carried out a prospective study  in  which  45  patients  with   SCS  were    randomly selected for surgery 
(n = 23) or conservative management (n = 22); mean duration of follow-up was about 8 years. They found that 
diabetes mellitus normalized or improved in about 2/3 of patients in the surgical group; on the other hand, 
some worsening of diabetes was noted in conserva- tively managed patients. Interestingly, Chiodini et al. [52] 
published a retrospective controlled study on 108 patients followed  up  for  18–48 months,  in  which  
adrenalectomy was recommended to all patients with SCS and to all patients without SCS but with mass size 
[4 cm or size increasing by [1 cm during the follow-up. Adrenalectomy improved glucose levels not only in 
patients with SCS, but also in patients without SCS, compared with patients treated conservatively. 
All these studies suggest that laparoscopic adrenalec- tomy appears more beneficial than conservative manage- 
ment for patients with SCS. This conclusion should be viewed with caution because of some methodological 
shortcomings of the studies, including the lack of a formal comparison between the patients who were 
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operated and those who were not and the fact that medical treatment of associated clinical conditions was not 
standardized between groups. 
On the other hand, other studies have reported no changes in glucose metabolism after adrenalectomy [40, 42]. 
Sereg et al. [40] carried out a retrospective uncon- trolled study, in which 47 out of 125 patients with clini- 
cally non-functioning adrenal adenomas underwent adrenalectomy, whereas 78 patients were followed up 
conservatively; these patients were re-assessed after a  mean follow-up time of about 9 years. The frequency of 
impaired glucose tolerance or diabetes mellitus did not significantly differ between patients treated and not 
treated with adrenalectomy. We recently published a prospective study on 118 patients followed up for 1–10 
years  reporting 
that adrenalectomy did not improve glucose levels in patients with SCS (n = 6), compared with patients treated 
conservatively (n = 10) or patients who underwent adre- nalectomy for non-functioning adenomas (n = 6) [42]. 
In all, the follow-up studies did not show a clear beneficial effect of surgery on glucose metabolism in SCS, 
but it has to be pointed out that adrenalectomy was not recommended for treatment of SCS, which was 
diagnosed only in a minority of patients submitted to surgery. These results also suggest that clinical 
improvement after adrenalectomy was not restricted to patients with SCS, casting some doubts on a cause-and- 
effect relationship. Moreover, it has to be pointed out that medical treatment was not standardized across the 
different groups in the different studies. 
Based on the controversial data about the effect of adrenalectomy on glucose metabolism in SCS patients, the 
recent AME Position Statement on AI [29] did not make any recommendation on this point, stating that ‘‘data 
are insufficient to make any recommendation for or against surgery in patients with SCS.’’ Similarly, the 
AACE/AAES Medical Guidelines [53] for the management of AI repor- ted likewise that, in patients with 
SCS, until further evi- dence is available regarding the long-term benefits of adrenalectomy, ‘‘surgical 
resection should be reserved for those with worsening of hypertension, abnormal glucose tolerance, 
dyslipidemia, or osteoporosis (recommendation with a low level of evidence).’’ Moreover, the NIH state- of-
the-science statement [21] suggested that ‘‘either adre- nalectomy or careful observation is a treatment option 
for patients with subclinical autonomous glucocorticoid hypersecretion.’’ 
Thus, the discordant results of above detailed studies, summarized in Table 2, seem to preclude any stringent 
recommendation of adrenalectomy for the management of glucose impairment in SCS. 
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Data from high-quality large prospective randomized trials are lacking to guide the optimal management of 
metabolic alterations of SCS and to indicate the superiority of a surgical or a non-surgical approach. These 
studies should include both surgically treated and adequately medically treated patients with and without SCS 
and  should provide for an adequate follow-up period of observation. 
Alternatively to adrenalectomy, drugs improving insulin sensitivity, such as metformin, or drugs increasing   
insulin secretion, such as sulfanylureas and miglitinides, could be used as second-line therapy in patients with 
SCS, and insulin analogs should be used if hyperglycemia is not corrected by oral hypoglycemic agents [20], 
although studies evaluating, in a comparative way, the best medical treatment of impaired glucose metabolism 
are lacking. Moreover, as insulin resistance and cardiovascular risk persist after correction of hypercortisolism, 
as demon- strated in patients with overt CS [19, 20], adequate treat- ment of concomitant diabetes and other 
comorbidities is mandatory also in patients with  SCS. 
In the past few years, aberrant cortisol responses to several stimuli due to the expression of aberrant receptors 
on adrenal cells have been reported in patients with SCS associated to bilateral incidentalomas [54]. Because 
these aberrant receptors may be specific pharmacological targets for controlling cortisol secretion, their 
detection deserves particular interest and some therapeutical protocols have been developed [20]. 
 
Subclinical Cushing’s syndrome in patients with diabetes mellitus type  2 
It is well known that diabetes mellitus represents a major determinant of the basal tone of the HPA axis, with 
an increased activity of HPA axis being reported in the pres- ence of chronic complications as well as a bad 
glycemic control [55–57]. 
Conversely, chronic hypercortisolism might cause dia- betes mellitus itself [19, 20]. In fact, CS is commonly 
complicated with an impairment of glucose metabolism, which is often clinically manifested as diabetes 
mellitus, prevalence of which varies between 20 and 50% [19, 20]. On the other hand, from 1996 various 
studies have shown a prevalence of unsuspected CS, mainly a SCS, in patients with type 2 diabetes, ranging 
from 0 to 9.4%, although a surgical improvement was attained in a minority of cases [58–67]. 
The method of screening was the 1-mg DST in all the cases except in at least two studies, where night salivary 
cortisol was used [64, 67]; moreover, the studies had a dif- ferent experimental design, as the diabetic 
population stud- ied differed across the studies (Table 3). In particular, several studies included patients with 
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clinical features making more likely a diagnosis of hypercortisolism, either hospitalized [58, 60, 61, 64] or 
outpatients [65–67], while only in one study [63] adult patients with newly diagnosed diabetes mellitus not 
selected for clinical characteristic were studied. 
In a retrospective study on 90 diabetic patients with BMI > 25 and HbA1c > 9% Leibowitz et al. [58] found 
that about 3% of patients had a definitive diagnosis of SCS. In a prospective study on 200 overweight patients 
with poorly controlled type 2 diabetes, Catargi et al. [60] reported 2% prevalence of SCS. In a prospective 
case– control study, Chiodini et al. [61] reported a prevalence of 9.4% in a group of 294 overweight/obese 
patients with poorly controlled diabetes compared with 189 controls. Recently, Taniguchi et al. [64] found a 
2.6% prevalence of SCS in a sample of 77 inpatients with type 2 diabetes. 
However, the prospective study of Reimondo et al. [63] recently showed partially different results, as 1% of 
100 consecutive patients with newly diagnosed diabetes was found to have a pituitary-dependent CS; in this 
study, a different population of patients with newly diagnosed diabetes mellitus, not selected for any clinical 
character- istic, were evaluated, with half of them with an acute presentation requiring emergency admission. 
All these above mentioned studies indicate that a sys- tematic screening of hypercortisolism in the diabetic 
population might be useful and  recommended. 
On the other hand, the conclusions of at least three other studies [65–67], similarly conducted in patients with 
an elevated ‘‘a priori’’ probability of hypercortisolemic, were opposite. In fact, the authors did not find any 
case of SCS in their group of diabetic patients, and so they concluded that widespread screening of for CS in 
type 2 diabetic population is unjustified. 
Two main issues are key to the justification of large- scale screening of CS. First, is occult CS associated with 
a more severe metabolic and cardiovascular disease? Second, does its cure have a beneficial impact on the 
outcome of patients? These issues remain mostly undefined by the available studies, because of the small 
number of diabetic patients found to have CS and submitted for specific treatment. In addition, none of the 
previous studies repor- ted on long-term data after successful treatment of occult CS. Discrepant results were 
reported as to the first point [60, 61], although amelioration of diabetes control has been reported in the few 
patients who attained remission of hypercortisolism [60, 61, 63]. 
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In summary, the results of these studies do not allow us to make definitive conclusion on the utility of the 
screening for CS in patients with diabetes mellitus, and no consensus does exist, at present, on this topic as 
well as on the timing of such screening. 
  
Conclusions 
Based on the data above reported, although there is convincing evidence in the literature that even a mild 
hyper- cortisolemia is associated with alterations of glucose metabolism, it is our opinion that evidence is 
insufficient to conclude that the simple correction of chronic, even mild, hypercortisolism can completely 
revert metabolic, mainly glycemic alterations. Focusing on patients with SCS asso- ciated to AI, it is not, at 
present, clarified whether surgery is preferable to a nonsurgical approach to improve glyce- mic control. Until 
data from high-quality prospective studies will become available, we should recommend sur- gery to younger 
patients with SCS and to patients who present comorbidities potentially linked to cortisol excess, of recent 
onset, difficult to control or progressively deteriorating. 
At the same time, considering the variability of the prevalence of Cushing’s syndrome in patients with diabetes 
mellitus type 2 reported in the literature, no agreement does exist whether screening for CS can be useful and 
recom- mended in those patients. For all the above mentioned reasons, along with the associated high costs 
and workload, it appears that a nationwide screening program for occult CS in all patients with type 2 diabetes 
is not worthy. At the 
  
 
  
same time, it is our opinion that an hormonal screening  with 1-mg DST may be recommended only in diabetic 
patients with clinical features making more likely a diagnosis of CS, like difficult-to-treat diabetes  associated 
with clinical comorbidities potentially linked to hypercortisolism. 
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